“The first-of-its-kind pivotal trial of an mRNA-based pandemic influenza vaccine underscores the potential of this technology to reshape how we confront emerging pathogens,” said Dr. Richard Hatchett, CEO of CEPI. “If successful, these efforts could transform our ability to respond swiftly and equitably to one of the world’s most enduring threats.”

The FDA has assigned mRNA-1010 a PDUFA target date of 5 August 2026. If approved, mRNA-1010 will be the first seasonal influenza mRNA vaccine on the market.

Moderna MRNA reported that the European Commission (EC) has granted marketing authorization for mCombriax (mRNA-1083), its mRNA combination vaccine for active immunization for the prevention of influenza disease and COVID-19 caused by SARS-CoV-2 in individuals 50 years of age and older.

A new study from the University of Gothenburg may help guide the development of better influenza vaccines. Memory cells in the nose slow the influenza virus as soon as it enters the body. They reduce viral levels and may help protect against more severe illness.

Vaccination with a higher dose of the influenza vaccine may reduce the risk of developing dementia among older adults.

Older adults and immunocompromised individuals in England face a disproportionately higher burden of severe influenza outcomes and hospitalizations.

Under new Defense Department guidance, annual influenza vaccines are now voluntary for all active duty and reserve service members.

Deep in the lungs, resident memory B cells stand guard against influenza reinfection—but whether they remain there may depend on how strongly they are signaled through their own receptors. New research using an animal model of influenza infection provides fresh insight into how these cells form and persist,